Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

APPROVED_FOR_MARKETING

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GE Healthcare has recently submitted a New Drug Application (NDA) for Iobenguane I 123 Injection (\[123I\]mIBG (AdreView)) as a diagnostic nuclear imaging agent for the detection of primary or metastatic neuroblastoma and pheochromocytoma. The present protocol establishes an Expanded Access program to provide AdreView to pediatric medical centers and hospitals that treat neuroblastoma patients. AdreView will be provided for use in diagnostic assessment of patients with known or suspected neuroblastoma for whom there is an appropriate clinical indication for \[123I\]mIBG imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Expanded Access Protocol Using 131I-MIBG

NCT01590680

Neuroblastoma Pheochromocytoma Paraganglioma

AVAILABLE

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

NCT00126412

Pheochromocytoma Neuroblastoma

COMPLETED PHASE3

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

NCT01163383

Neuroblastoma Childhood Metastatic Pheochromocytoma

AVAILABLE

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT00107289

Neuroblastoma Pheochromocytoma

RECRUITING PHASE2

MIBG for Refractory Neuroblastoma and Pheochromocytoma

NCT01850888

Relapsed Neuroblastoma Metastatic Pheochromocytoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The sponsor will provide \[123I\]mIBG as a single dose in a ready-to-use vial. All patients greater than or equal to 18 years of age and children with a weight of greater than or equal to 70 kg will receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq \[9.0 to 11 mCi\]) of \[123I\]mIBG. Children \<16 years of age (with a weight of 8-70 kg) will receive an activity of \[123I\]mIBG calculated on the basis of a reference activity for an adult scaled to body weight. Each investigator is responsible for obtaining the appropriate thyroid blockade agent and for its administration in accordance with national and local regulations and guidelines. Approximately 24 (± 6) hours following administration of \[123I\]mIBG all patients will return to the clinic for scintigraphic imaging. Imaging will be performed as per the standard procedures of the investigational site. This should include at a minimum total body planar scintigraphy. Single photon emission computed tomography (SPECT) may be performed following planar scintigraphy, as appropriate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroblastoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iobenguane I 123 Injection

1-10 mCi administered intravenously

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AdreView

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient has known or suspected neuroblastoma and is undergoing evaluation of disease status (for which a mIBG scintigraphic examination is clinically appropriate).
* The patient is able and willing to comply with study procedures and a signed and dated informed consent is obtained from the patient (or their legal guardian.

Exclusion Criteria

* The patient uses medications that are known to interfere with \[123I\]mIBG uptake and these medications cannot be safely withheld for a least 24 hours before study procedures.

Eligible Sex

ALL

Accepts Healthy Volunteers

No